샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793760

세계의 큐열 시장

Q Fever
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 367 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

큐열 세계 시장은 2030년까지 5억 810만 달러에 달할 전망

2024년에 4억 2,560만 달러로 추정되는 큐열 세계 시장은 2030년에는 5억 810만 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 3.0%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 급성 큐열는 CAGR 2.2%를 기록하며 분석 기간 종료시에는 3억 1,210만 달러에 달할 것으로 예측됩니다. 만성 큐열 분야의 성장률은 분석 기간 동안 CAGR 4.3%로 추정됩니다.

미국 시장은 1억 1,590만 달러로 추정, 중국은 CAGR 5.5%로 성장 예측

미국의 큐열 시장은 2024년에 1억 1,590만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 9,870만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 5.5%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.2%와 2.3%로 예측됩니다. 유럽에서는 독일이 CAGR 1.7%로 성장할 것으로 예측됩니다.

세계의 큐열 시장 - 주요 동향과 촉진요인 정리

큐열이 공중보건 및 수의학 감시의 우선순위로 떠오른 이유는 무엇인가?

큐열은 Coxiella burnetii라는 박테리아에 의해 발생하는 인수공통전염병으로 사람과 가축 모두에게 심각한 건강상의 위험을 초래합니다. 큐열의 발병은 종종 과소 진단되는 반면, 동물과 인간의 접촉이 두드러지는 전 세계 농촌 지역과 도시 주변 지역에서 기록되고 있습니다. 이 질병은 주로 수의사, 도축장 노동자, 낙농가, 목축업자 등 가축과 직접 접촉하는 사람들이 걸립니다. 인간의 경우, 큐열은 급성 또는 만성 형태로 나타나며, 심한 경우 발열성 질환, 폐렴, 심내막염을 유발합니다.

인수공통전염병의 확산과 가축 생산의 강화로 인해 Q fever의 감시와 진단이 중요시되고 있습니다. 기후 변화, 가축 거래의 세계화, 토지 이용 패턴의 변화는 이전에 영향을 받지 않았던 지역에서 C. burnetii의 확산을 촉진하고 있습니다. 또한, 이 박테리아의 환경 내성과 에어로졸 감염 가능성은 바이오 보안과의 연관성을 강조하고 있습니다. 공중 보건 당국은 현재 수의학 및 인체 개입을 조정하여 발병을 통제하는 통합적인 '원헬스(One Health)' 전략을 우선순위에 두고 있습니다.

어떤 진단약, 치료 전략, 그리고 위험 집단이 시장 역학을 정의하고 있는가?

큐열의 진단은 혈청학적 검사와 분자생물학적 검사의 조합에 의존합니다. 간접면역형광법(IFA)이 여전히 표준으로 사용되고 있지만, ELISA 및 PCR 기반 기술이 급성 및 만성 사례 모두에서 채택되고 있습니다. Point of Care 진단법은 발병이 발생하기 쉬운 농촌 환경에서의 실지 전개가 검토되고 있습니다. 그러나 초기 임상 증상의 특이성이 낮아 진단이 늦어지고, 경험적 치료가 부적절한 경우가 많아 질병의 진행과 합병증의 위험이 높아집니다.

독시사이클린은 급성 큐열에 대한 표준 치료법이며, 고위험 직업적 노출에 대한 1차 선택 약물입니다. 만성 큐열, 특히 심장 병변이 동반된 경우, 독시사이클린과 하이드록시클로로퀸을 병용하여 장기적인 치료가 필요합니다. 호주는 주로 농업 종사자를 대상으로 한 큐열 백신(Q-Vax)이 승인된 몇 안 되는 국가 중 하나입니다. 특히 네덜란드, 아프리카 일부, 중앙아시아 등 발병률이 높은 지역에서는 보다 안전하고 집단 예방접종이 가능한 차세대 백신 개발이 진행되고 있습니다.

바이오 보안 대책, 질병 모니터링, 규제 대응이 방역 전략에 어떤 영향을 미치고 있는가?

수의학적 감시 강화와 가축 관리 관행은 방역의 핵심입니다. 가축의 격리, 분만장소 감시, 태반과 분뇨의 적절한 처리, 가축의 이동 통제 등의 조치는 박테리아 배출과 에어로졸 확산을 억제하는 데 매우 중요합니다. 발병 지역에서는 염소, 양, 소에 대한 정기적인 혈청검사를 실시하고, 도태 및 백신 접종을 통해 감염 위험을 억제해야 합니다.

공중보건 대응은 조기 경보 시스템, 발병 모델, 의무적 질병 통지 프로토콜을 포함하도록 진화하고 있습니다. 실시간 GIS 매핑, 환경 샘플링, 날씨에 기반한 위험 모델링은 보건 당국이 잠재적인 발병을 예측하고 선제적으로 대응할 수 있도록 돕고 있습니다. 큐열 모니터링을 보다 광범위한 인수공통전염병 감시 체계에 통합하는 것은 WHO, OIE, FAO 등 국제기구의 원헬스 이니셔티브(One Health Initiative)에 의해 지원되고 있습니다. 수의학 시스템과 의료 보건 시스템 간의 규제 정합성은 신속한 봉쇄와 대응 조정을 가능하게 하는 중요한 요소입니다.

세계 큐열 진단 및 치료제 시장의 성장을 촉진하는 요인은 무엇인가?

세계 큐열 시장의 성장은 질병에 대한 인식의 증가, 진단 도구의 개선, 인수공통전염병 발생 빈도의 증가에 의해 이루어지고 있습니다. 축산업, 동물 운송, 수의사 업무에서 직업적 노출이 큐열 발생률의 주요 원동력이 되고 있습니다. 신흥 경제국에서 상업적 축산업이 확대되고, 바이오 보안이 미흡한 상황에서 인간과 동물의 병원체 전파 위험이 증가하면서 질병 관리 솔루션에 대한 수요가 증가하고 있습니다.

COVID-19 이후 생물학적 대비 강화와 팬데믹 감시를 위한 노력으로 인해 정부와 기관들은 인수공통전염병 조사, 진단 역량 강화, 농촌 지역 보건 봉사 프로그램에 대한 투자를 촉진하고 있습니다. 호주, 네덜란드, 케냐, 중국 등지에서 발생한 지역적 큐열 발생은 감시 및 백신 개발 연구를 위한 자금 증가로 이어졌습니다. 또한, Q Fever를 다중 병원체 바이오 서베일런스 시스템에 통합함으로써 멀티플렉스 진단 및 모바일 랩 시장이 확대되고 있습니다.

이 분야의 주요 기업으로는 bioMerieux, Thermo Fisher Scientific, QIAGEN, Ceva Sante Animale, Alere(Abbott) 등이 있습니다. 공중보건 시스템이 국가 인수공통전염병 대책의 틀 안에서 큐열을 제도화하고, 농촌 지역에서의 진단 접근성을 우선시하며, 수의사 검진 프로그램을 확대함에 따라 시장 성장이 가속화될 것으로 예상됩니다. 원헬스 접근법이 감염병 전략의 중심이 되면서, 큐열은 지속적인 진단 및 치료 혁신이 필요한 중요한 인수공통전염병 문제로 남아있을 것으로 예상됩니다.

부문

유형(급성 큐열, 만성 큐열), 약물 유형(항생제, 항말라리아제, 코르티코스테로이드제, 기타 약물 유형), 최종사용자(병원 최종사용자, 클리닉 최종사용자, 조사기관 최종사용자)

조사 대상 기업 사례

  • AtoxBio
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • BioMerieux SA
  • Ceva Sante Animale
  • CSL Limited
  • Elanco Animal Health
  • Johnson & Johnson Services, Inc.
  • Melinta Therapeutics, Inc.
  • Merck KGaA
  • Merck & Co., Inc.
  • Pfizer Inc.
  • QIAGEN N.V.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries
  • Thermo Fisher Scientific
  • Valneva SE
  • Vaxin Inc.
  • Virbac
  • Yashica Pharmaceuticals Pvt. Ltd

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.26

Global Q Fever Market to Reach US$508.1 Million by 2030

The global market for Q Fever estimated at US$425.6 Million in the year 2024, is expected to reach US$508.1 Million by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Acute Q Fever, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$312.1 Million by the end of the analysis period. Growth in the Chronic Q Fever segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$115.9 Million While China is Forecast to Grow at 5.5% CAGR

The Q Fever market in the U.S. is estimated at US$115.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$98.7 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Q Fever Market - Key Trends & Drivers Summarized

Why Is Q Fever Emerging as a Public Health and Veterinary Surveillance Priority?

Q Fever, caused by the bacterium Coxiella burnetii, is a zoonotic disease that poses significant health risks to both humans and livestock. While often underdiagnosed, Q Fever outbreaks are increasingly documented across rural and peri-urban regions worldwide, where animal-human interface is pronounced. The disease primarily affects individuals in direct contact with farm animals, including veterinarians, abattoir workers, dairy farmers, and herders. In humans, Q Fever can present in acute or chronic forms, leading to febrile illness, pneumonia, or endocarditis in severe cases.

The growing incidence of zoonotic spillover events and intensified livestock production have prompted increased focus on Q Fever surveillance and diagnostics. Climate change, globalization of animal trade, and shifting land-use patterns are contributing to the spread of C. burnetii in previously unaffected geographies. Additionally, the bacterium’s environmental resilience and potential for aerosol transmission underscore its biosecurity relevance. Public health authorities are now prioritizing integrated “One Health” strategies to control Q Fever outbreaks through coordinated veterinary and human health interventions.

Which Diagnostics, Treatment Strategies, and At-Risk Populations Are Defining Market Dynamics?

Diagnosis of Q Fever relies on a combination of serological and molecular tests. Indirect immunofluorescence assay (IFA) remains the gold standard, while ELISA and PCR-based techniques are increasingly employed for both acute and chronic cases. Point-of-care diagnostics are being explored for field deployment in outbreak-prone rural settings. However, the low specificity of early clinical symptoms often leads to delayed diagnosis and inappropriate empirical treatment, increasing the risk of disease progression and complications.

Doxycycline is the standard treatment for acute Q Fever and remains the first-line therapy for high-risk occupational exposure. Chronic Q Fever, especially with cardiac involvement, requires prolonged treatment combining doxycycline with hydroxychloroquine. Vaccination plays a limited but significant role-Australia remains one of the few countries with an approved Q Fever vaccine (Q-Vax), primarily targeting agricultural workers. Efforts are underway to develop next-generation vaccines with broader safety profiles and mass immunization potential, especially in high-incidence regions like the Netherlands, parts of Africa, and Central Asia.

How Are Biosecurity Measures, Disease Monitoring, and Regulatory Responses Influencing Control Strategies?

Enhanced veterinary surveillance and livestock management practices are central to Q Fever control. Measures such as animal quarantine, monitoring of parturition areas, proper disposal of placenta and manure, and control of animal movement are critical in reducing bacterial shedding and aerosol dispersion. In endemic zones, routine serological testing in goats, sheep, and cattle-along with culling or vaccination strategies-is being mandated to limit transmission risks.

Public health responses are evolving to include early-warning systems, outbreak modeling, and mandatory disease notification protocols. The adoption of real-time GIS mapping, environmental sampling, and weather-based risk modeling is helping health authorities anticipate and pre-empt potential outbreaks. Integration of Q Fever monitoring into broader zoonotic disease surveillance frameworks is being supported by international bodies such as WHO, OIE, and FAO under the One Health Initiative. Regulatory alignment between veterinary and medical health systems is a key enabler for rapid containment and response coordination.

What Factors Are Driving the Growth of the Global Q Fever Diagnostics and Therapeutics Market?

The growth in the global Q Fever market is driven by rising disease awareness, improved diagnostic tools, and the increasing frequency of zoonotic disease outbreaks. Occupational exposure in livestock farming, animal transport, and veterinary practice continues to be a major driver of Q Fever incidence. The expansion of commercial livestock farming in developing economies, coupled with inadequate biosecurity practices, is amplifying human-animal pathogen transmission risks and driving demand for disease control solutions.

Heightened bio-preparedness and pandemic surveillance efforts post-COVID-19 are catalyzing government and institutional investments in zoonotic disease research, diagnostic capacity building, and rural health outreach programs. Regional Q Fever outbreaks in Australia, the Netherlands, Kenya, and China have led to increased funding for surveillance and research on vaccine development. Moreover, the integration of Q Fever into multi-pathogen biosurveillance systems is expanding the market for multiplex diagnostics and mobile laboratories.

Leading players in the space include bioMerieux, Thermo Fisher Scientific, QIAGEN, Ceva Sante Animale, and Alere (Abbott). Market growth is expected to accelerate as public health systems institutionalize Q Fever within national zoonotic disease frameworks, prioritize rural diagnostic access, and scale veterinary screening programs. As One Health approaches become central to infectious disease strategy, Q Fever is positioned to remain a critical zoonotic concern demanding sustained diagnostic and therapeutic innovation.

SCOPE OF STUDY:

The report analyzes the Q Fever market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Acute Q Fever, Chronic Q Fever); Medication Type (Antibiotics, Antimalarial, Corticosteroids, Other Medication Types); End-Use (Hospitals End-Use, Clinics End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AtoxBio
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • BioMerieux SA
  • Ceva Sante Animale
  • CSL Limited
  • Elanco Animal Health
  • Johnson & Johnson Services, Inc.
  • Melinta Therapeutics, Inc.
  • Merck KGaA
  • Merck & Co., Inc.
  • Pfizer Inc.
  • QIAGEN N.V.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries
  • Thermo Fisher Scientific
  • Valneva SE
  • Vaxin Inc.
  • Virbac
  • Yashica Pharmaceuticals Pvt. Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Q Fever - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Zoonotic Diseases Throws the Spotlight on Q Fever Surveillance Programs
    • Expansion of Livestock Farming and Dairy Production Propels Disease Transmission Risks
    • Increasing Demand for Veterinarian-Led Diagnostics Drives Adoption of Q Fever Testing Kits
    • Development of Serological and PCR Assays Enhances Early Detection Capabilities
    • Government Mandates on Animal Vaccination Strengthen Control Program Implementation
    • Growing Public Health Focus on Bioterrorism Risk Accelerates Research on Coxiella burnetii
    • Surge in Tick-Borne and Aerosol-Transmitted Infections Spurs Biosafety Investments
    • Partnerships With Veterinary Institutions Fuel Epidemiological Tracking Initiatives
    • Emerging Molecular Tools and Genotyping Methods Drive Strain Differentiation Efficiency
    • Rising Integration of Q Fever Screening in Livestock Export Protocols Expands Testing Scope
    • Focus on Cross-Reactivity Reduction Improves Diagnostic Accuracy
    • Expansion of One Health Initiatives Strengthens Human-Animal Disease Surveillance Systems
    • Innovation in Point-of-Care Testing Devices Enhances On-Farm Screening Options
    • Increasing Funding for Rickettsial Disease Research Promotes Novel Therapeutic Exploration
    • Regulatory Endorsements for Targeted Antibiotic Therapies Drive Treatment Compliance
    • Development of Cold Chain-Independent Reagents Improves Rural Testing Accessibility
    • Rising Awareness Campaigns Among Livestock Workers Propel Preventive Healthcare Demand
    • Expansion of Agri-Biotech Companies in Developing Regions Supports Commercial Adoption
    • Investment in Portable Lab Equipment Enhances Disease Monitoring in Remote Areas
    • Growth in Travel-Associated Infections and Occupational Exposure Fuels Prophylaxis Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Q Fever Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Q Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Q Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antimalarial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antimalarial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Antimalarial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Medication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Medication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Medication Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Q Fever by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Q Fever by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Q Fever by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Q Fever by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Q Fever by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Q Fever by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Q Fever by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제